Why is there persistent disease despite biologic therapy? Importance of early intervention (Q33821890)

29 July 2017

4 references

13 March 2019

17 June 2019

30 June 2019

14 November 2020

Why is there persistent disease despite biologic therapy? Importance of early intervention (English)

1 reference

disease-modifying antirheumatic drug

29 July 2017

4 references

13 March 2019

17 June 2019

30 June 2019

14 November 2020

1 reference

14 November 2020

Paul Emery

0 references

language of work or name

1 reference

1 January 2014

1 reference

Arthritis Research and Therapy

29 July 2017

published in

5 references

29 July 2017

13 March 2019

17 June 2019

30 June 2019

14 November 2020

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

115

1 reference

Creative Commons Attribution 4.0 International

29 July 2017

4 references

13 March 2019

17 June 2019

30 June 2019

on focus list of Wikimedia project

14 November 2020

copyrighted

0 references

ScienceSource

0 references

cites work

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075238

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075238

Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075238

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075238

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075238

Toll-like receptors in rheumatoid arthritis joint destruction mediated by two distinct pathways

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075238

Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study

4 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FAR4594

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FAR4594

A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075238

An immunological biomarker to predict MTX response in early RA.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075238

Delay in imaging versus clinical response: A rationale for prolonged treatment with anti–tumor necrosis factor medication in early rheumatoid arthritis

29 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FAR4594

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25167379

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25167379

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/AR4594

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference